Indolium-based stabilizers of hydrophobic drugs
AssigneeTechnion Research & Development Foundation Limited
InventorsYosi SHAMAY, Yuval HARRIS, Danna NIEZNI, Hagit SASON
Life of this patent
Estimating the term…
Abstract
A composition containing a mixture of oligomers or co-oligomers obtained by exposing an indolium-based monomer, optionally together with an additional monomer selected from dopamine, L-dopa, norepinephrine, serotonin, and a mixture thereof, to a basic buffer. The composition may further contain a hydrophobic substance such as a drug or dietary supplement, stabilized by the oligomers above.
Claims33
A composition comprising a mixture of oligomers obtained by exposing an indolium-based monomer of formula I,
- wherein:
- R1, R2, and R3 each independently is (C1-C6)alkyl optionally interrupted with one or more heteroatoms selected from the group consisting of O, N, and S;
- R4 is (C1-C12)alkyl optionally interrupted with one or more heteroatoms selected from the group consisting of O, N, and S, substituted with one or more groups each independently selected from the group consisting of —SO3−, —COO−, —PO3−2, —OH, —NH2, —N+(R′)3, phosphocholine (—OPO3−—(CH2)2—N+(CH3)3), and acetoxyethyl phospocholine (—CH2—C(O)—O—(CH2)2—OPO3−—(CH2)2—N+(CH3)3), wherein R′ each independently is (C1-C6)alkyl, or (C3-C7)cycloalkyl, or two of the R's together with the nitrogen atom to which they are attached form a 5-9 membered ring;
- R5, R6, R7, and R8 each independently is selected from the group consisting of H, —OH, (C1-C6)alkyl, —O—(C1-C6)alkyl, —CO(C1-C6)alkyl, —COO(C1-C6)alkyl, —N(R9)2, —CON(R9)2, —S—(C1-C6)alkyl, and —SH;
- or two adjacent of R5, R6, R7, and R8 together with the carbon atoms to which they are attached form (C6-C14)aryl or 5- to 14-membered heteroaryl, optionally substituted by one or more groups each independently selected from the group consisting of halogen, —OH, (C1-C6)alkyl, —O—(C1-C6)alkyl, —CO(C1-C6)alkyl, —COO(C1-C6)alkyl, —N(R9)2, —CON(R9)2, —S—(C1-C6)alkyl, and —SH, and the other of R5, R6, R7, and R8 each independently is selected from the group consisting of H, —OH, (C1-C6)alkyl, —O—(C1-C6)alkyl, —CO(C1-C6)alkyl, —COO(C1-C6)alkyl, —N(R9)2, —CON(R9)2, —S—(C1-C6)alkyl, and —SH;
- and
- R9 each independently is H, halogen, (C1-C6)alkyl, (C3-C11)cycloalkyl, (C5-C11)cycloalkenyl, heterocyclyl, aryl, heteroaryl, or two R9's together with the nitrogen atom to which they are attach form a 5- to 7-membered ring,
- optionally together with an additional monomer selected from the group consisting of dopamine, L-dopa, norepinephrine, serotonin, and a mixture thereof, to a basic buffer.
(canceled)
(canceled)
(canceled)
The composition of claim 34, wherein said hydrophobic substance is a drug selected from the group consisting of an anticancer (chemotherapeutic) drug, antifungal drug, antibacterial drug, antiviral drug, immunosuppressive drug, anti-hyperlipidemic drug, nonsteroidal anti-inflammatory drug, cardiac drug, neurological drug, psychoactive drug, drug of abuse, alkaloid, antibiotic, bioactive peptide, steroid, steroid hormone, selective estrogen receptor modulator (SERM), 5-alpha reductase inhibitor, peptide hormone, interferon, interleukin, narcotic, nucleic acid, pesticide, and prostaglandin.
The composition of claim 34, wherein said hydrophobic substance is a hydrophobic drug comprising a 2-(N-anilino)pyrimidine group coupled to π-conjugated system directly or via a nitrogen atom.
29-31. (canceled)
Dependencies are inferred from the claim text.